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A commentary on
Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy
by Jaunmuktane, Z., Mead, S., Ellis, M., Wadsworth, J. D. F., Nicoll, A. J., Kenny, J., et al. (2015).
Nature 525, 247–250. doi: 10.1038/nature15369
With incubation time ranging from 5 to 40 years, Creutzfeldt-Jakob disease (CJD) is a deadly
condition caused by the accumulation of toxic forms of the prion protein in the brain. Between the
50 s and 80 s, hundreds of patients developed CJD after being treated with cadaveric human growth
hormone (c-hGH) contaminated with prion protein. This has led several countries to develop
cohorts in order to follow these patients and understand the burden of prion disease in their lives
over time.
Multiple studies were published linking amyloid-β (Aβ) deposits in the brain—a key feature
of Alzheimer’s disease (AD)—to prion disease patients that acquired it through several different
sources (Watanabe and Duchen, 1993; Preusser et al., 2006; Tousseyn et al., 2015). In general,
both Aβ deposits and prion protein deposits occurs by a nucleation-dependent polymerization
process in which oligomeric “seed” proteins trigger the formation of an ordered nucleus that may
rapidly grows into larger polymer fibrils (Harper and Lansbury, 1997). Recently, Jaunmuktane et al.
(2015) performed an autopsy study providing evidence of a possible prion-like transmission of the
amyloid-β protein in prion disease patients.
The work evaluated brain tissue from 8 patients that died between 36 and 51 years of age
of iatrogenic CJD (iCJD) and found abnormal levels of Aβ protein in 7 of them. Such findings
were intriguing since age-matched patients with different kinds of prion disease showed extremely
rare occurrence of Aβ deposits, engaging researchers in a deeper investigation on the relationship
between prion and Aβ proteins.
First, the authors excluded any genetic predisposition that these patients might have for several
neurodegenerative diseases, including AD, amyotrophic lateral sclerosis, frontal temporal dementia
and Parkinson’s disease, screening for variations in ApoE and 16 other alleles. Such extensive
screening wasn’t performed in similar past studies (Hainfellner et al., 1998; Irwin et al., 2013).
None of these patients presented causal mutations, but three of them presented possible risk factor
alleles for frontotemporal dementia/AD (patient 4) and frontotemporal dementia (patients 6 and
8). AlthoughAβ deposits are not common in frontotemporal dementia, these patients were the ones
presenting widespread cortical and leptomeningeal cerebral Aβ angiopathy. Anyhow, considering
the large controversy relating genetic risk factors other than ApoE and actual AD development,
such minor mutations seem negligible in the presented scenario.
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Next, they compared the Aβ burden in these patients with
other prion disease patients, in an attempt to connect the
iatrogenically transmission specifically to Aβ burden. None of the
CJD patients in the same age strata showed similar Aβ pathology
using 4 different quantification methods, which the authors
interpreted as an evidence of human transmission. However,
the authors can’t exclude the possibility of a stimulation of
endogenous Aβ production by the prion protein, since other
studies with larger cohorts found considerable amyloidopathy in
the brain of sporadic CJD patients (Hainfellner et al., 1998; Irwin
et al., 2013; Tousseyn et al., 2015). This argues against the idea of
the Aβ burden being specific for iCJD.
Further, the authors checked for evidences of possible cross-
seeding (when one abnormal protein—called a seed—is capable
of modifying the folding of another type of protein) between
the two protein deposits. Interestingly, cross-seeding with α-
synuclein was already showed to occur with Aβ in vitro and
with tau in vivo (Waxman and Giasson, 2011; Ono et al., 2012).
The authors found an absence of co-localization between them
both in plaques and in vascular deposits, suggesting that these
pathologies might develop independently. However, as discussed,
the lack of co-localization is not enough to completely exclude
cross-seeding. Testing whether or not prion pathology might
induce Aβ aggregation in health animals might be of interest.
Also, they analyzed pituitary glands of AD patients for Aβ
and further supported the possibility of contamination of c-
GH batches with Aβ as well as prion proteins, as previously
described (Peden et al., 2007). The authors argued that both
proteins might have been present in the final preparation
and iatrogenically contaminated the patients. A biochemical
analysis of residual batches of c-GH for Aβ as well as their
use in animal models of propagation could shed light into
the matter.
Although Aβ is a hallmark of Alzheimer’s disease, no tau
pathology was found in the brain of such patients. The authors
suggested that, had the patients not died of prion disease, the
tau accumulation might have developed over time. It is indeed
known that tau pathology develops after the Aβ deposits in AD
(Jack et al., 2010), but with the presented findings is still uncertain
if they would or not develop tau pathology and AD.
Their hypothesis is supported by the fact that iatrogenic
transmission of Aβ has been demonstrated more than once
in mice by both intracerebral and peripheral routes (Meyer-
Luehmann et al., 2006; Eisele et al., 2009, 2010; Stöhr et al., 2012).
Also, Tousseyn et al. (2015) exposed human brain homogenates
to sporadic CJD human brain homogenates and found positive
Aβ labeling as well as hyperphosphorilated tau accumulation.
Recently, Ye et al. (2015) demonstrated that such seeds may stay
dormant in a mouse brain for months and still be pathological
once inoculated in another animal. It would be interesting to
see a parabiosis experiment showing that cerebral Aβ deposits in
transgenic mice, for example, could be transmitted to another,
health, mice through the blood.
Collectively, the literature still doesn’t support prion-like
transmission as a relevant form of developing AD. Since other
larger studies found controversial results, the next step to
test Jaunmuktane et al. (2015) hypothesis would be to obtain
data from larger cohorts of CJD patients. Once confirmed,
we can imagine two scenarios: a scientific fun-fact with little
epidemiological significance for the general population or a
revolution in AD prevention, patient management and treatment
development. Let’s wait for the next chapter.
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